Skip to main content

Table 2. Baseline demographic data, presentation of 104 patients with malignant pleural effusion

From: Chemical pleurodesis for malignant pleural effusion: which agent is perfect?

CharacteristicMean ± SD
n
Range
%
Age (mean ± SD, range), years57.55 ± 9.0222–74
Male, n (%)5048.1
Diabetes mellitus2423.7
Hypertension5754.8
Congestive heart failure1312.5
Hepatic dysfunction87.7
Smoker2826.9
Side of intervention, right, n (%)5956.7
ECOG score, n (%)  
 0–28076.9
 3–42120.2
 Unknown32.9
Effusion grade  
 Small (1–2)00
 Moderate (3–4)65.8
 Large (5)2625
 Massive (6)7269.2
Presenting symptom*  
 Dyspnea104100
 Chest pain3230.7
 Cough3937.5
 Chest pain and cough2423.1
Dyspnea score (NYHA)  
 NYHA II98.7
 NYHA III3634.6
 NYHA IV5956.7
Pleural fluid chemistry  
 Exudate104100
 Mean PH7.14 ± 0.226.87–7.48
 PH < 7.39389.4
 PH ≥ 7.31110.6
 Glucose (mg/dl)73.3 ± 25.124–119
 LDH (IU/L)1493± 294586–2862
Pleural fluid cytology  
 WBC (/μl)624.2± 58300–2216
 Mono (%)73.4± 3.665–87
 Malignant (%)12.3± 5.24–28
 RBC (/μl)19560± 58.71400–4800
  1. Eastern Cooperative Oncology Group (ECOG) performance status score runs from 0 to 5, where 0 is fully active, 1 is restricted in physical strenuous activity, 2 is unable to carry out any work activities, 3 is only able to carry out limited self-care activities, 4 is completely disabled, and 5 is dead
  2. Baseline effusion size was graded on chest radiograph immediately prior to trial intervention, using a validated grading system whereby grade 0 referred to no radiographic evidence of pleural fluid; grade 1, blunting of the costophrenic angle; grade 2 to 5, fluid occupying less than 25%, 25% to 50%, 51% to 75%, and more than 75% of the hemithorax, respectively
  3. *The presenting symptoms are non-mutually exclusive